Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

Lp(a)-lowering drug pelacarsen fails to cut heart attacks and strokes in major trial

Close-up view of an ECG reading on graph paper, displaying heart rhythm and pulse data for medical analysis.

Results presented at the American Heart Association Scientific Sessions 2026 show that pelacarsen, an investigational drug that lowers lipoprotein(a), reduced its target but did not reduce heart attacks and strokes. An anti-inflammatory heart drug from another company also failed to meet expectations this week.

High lipoprotein(a) remains an important, largely inherited risk marker for cardiovascular disease. The findings show that lowering a biomarker does not always translate into fewer clinical events.

Source: Medscape (AHA 2026)